Monitor upcoming Phase II trial enrollment for OcuRing-K and DeepSolar revenue disclosures in the next 6-K or 10-Q. The strengthened cash runway reduces near-term financing risk, but the lack of revenue visibility and increased net loss warrant caution.
Price Chart
Executive Summary
PRF Technologies reported a net loss of $2.8M for H1 2026 (up from $2.3M) but strengthened its cash position to $11.6M after a $10M equity raise. Pipeline advances include FDA IND clearance for OcuRing-K and positive preclinical data for PRF-110, while DeepSolar began generating revenue (undisclosed amount). No EPS or revenue guidance was provided, and the filing lacks hard financial surprises.
Key Facts
- Net loss attributable to shareholders: ~$2.8M for six months ended June 30, 2026 vs ~$2.3M in prior year period
- Cash, short-term deposits and equivalents: ~$11.6M as of June 30, 2026 (up from ~$4.2M at Dec 31, 2025)
- Raised $10.0M gross proceeds in May 2026 via standby equity purchase agreement (2,152,798 shares)
- FDA cleared IND for OcuRing-K, enabling Phase II trial in cataract surgery with enrollment expected H2 2026
- PRF-110 demonstrated 72-hour analgesic activity comparable to ZYNRELEF in preclinical study
- DeepSolar began recognizing revenue from commercial engagements (amount not disclosed)
- G&A expenses decreased ~39% YoY; R&D nearly tripled
Financial Impact
Net loss increased ~22% to $2.8M; cash position improved ~176% to $11.6M; $10M equity raise caused dilution of ~2.15M shares
Risk Factors
- Dilution from equity line facilities and future capital needs
- No disclosed revenue or EPS guidance — financial trajectory unclear
- Clinical trial risks for OcuRing-K and PRF-110
- Nasdaq continued listing requirements (low market cap of $3M)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3355915 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $0.7400 | awaiting T+60 | — | $0.7393 (−0.09%) |
Oct 23, 2026 3d ago | Press Release | $0.7400 | awaiting T+60 | — | $0.7393 (−0.09%) |
Sep 28, 2026 28d ago | 6-K | $0.9720 | awaiting T+60 | — | $0.7393 (−23.94%) |
Sep 24, 2026 4w ago | SC 13D | $0.9767 | awaiting T+60 | — | $0.7393 (−24.31%) |
Sep 16, 2026 5w ago | 6-K | $1.01 | awaiting T+60 | — | $0.7393 (−26.80%) |
Sep 4, 2026 7w ago | EFFECT | $0.9680 | awaiting T+60 | — | $0.7393 (+23.63%) |
Sep 3, 2026 7w ago | 6-K | $0.9792 | awaiting T+60 | — | $0.7393 (−24.50%) |
Sep 3, 2026 7w ago | Press Release | $0.9792 | awaiting T+60 | — | $0.7393 (−24.50%) |
Jul 27, 2026 13w ago | 6-K | $1.09 $0.7120 | ▼ −34.68% | ▼ −38.38% | $0.7393 (−32.17%) |
Jul 21, 2026 13w ago | 6-K | $1.20 $0.8180 | ▼ −31.83% | ▼ −35.81% | $0.7393 (−38.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers